Marketing-authorisation holder · United States
UCB, Inc.
43 medicines in 1 country, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
43 medicines in 1 country, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 43
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| BIMZELX160ml · Injectable | Bimekizumab | United States | Marketed | 2023 |
| Bimzelx320mg/2ml (160mg/2ml) · Injection | Bimekizumab | United States | Marketed | 2024 |
| Bimzelx160mg/ml · Injection | Bimekizumab | United States | Marketed | 2023 |
| Bimzelx320mg/2ml (160mg/2ml) · Injection | Bimekizumab | United States | Marketed | 2024 |
| BIPHETAMINE 12.56.25mg base; 6.25mg base · Capsule, extended release | Amphetamine resin complex, Dextroamphetamine resin complex | United States | Not marketed | 1955 |
| BIPHETAMINE 2010mg base; 10mg base · Capsule, extended release | Amphetamine resin complex, Dextroamphetamine resin complex | United States | Not marketed | 1955 |
| BIPHETAMINE 7.53.75mg base; 3.75mg base · Capsule, extended release | Amphetamine resin complex, Dextroamphetamine resin complex | United States | Not marketed | 1955 |
| BRIVIACT50mg/5ml (10mg/ml) · Solution | Brivaracetam | United States | Marketed | 2016 |
| BRIVIACT100mg | 10mg | 25mg | 50mg | 75mg · Tablet | Brivaracetam | United States | Marketed | 2016 |
| BRIVIACT10mg/ml · Solution | Brivaracetam | United States | Marketed | 2016 |
| Cimzia200mg/ml · Injection | Certolizumab pegol | United States | Marketed | 2019 |
| CIMZIA200mg · Injectable | Certolizumab pegol | United States | Marketed | 2008 |
| CO-GESIC500mg; 5mg · Tablet | Paracetamol, Hydrocodone | United States | Not marketed | 1982 |
| CORSYM4mg maleate/5ml; 37.5mg hcl/5ml · Suspension, extended release | Chlorpheniramine polistirex, Phenylpropanolamine polistirex | United States | Not marketed | 1984 |
| DEXACORT0.1mg phosphate/inh · Aerosol, metered | Dexamethasone | United States | Not marketed | 1962 |
| DEXACORT0.1mg phosphate/inh · Aerosol | Dexamethasone | United States | Not marketed | 1965 |
| FINTEPLA2.2mg base/ml · Solution | Fenfluramine | United States | Marketed | 2020 |
| FLUXID20mg | 40mg · Tablet, orally disintegrating | Famotidine | United States | Not marketed | 2004 |
| GASTROCROM100mg · Capsule | Cromolyn | United States | Not marketed | |
| IONAMIN15MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 30MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Capsule, extended release | Phentermine resin complex | United States | Not marketed | 1959 |
| KEMSTRO10MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · Tablet, orally disintegrating | Baclofen | United States | Not marketed | 2003 |
| KEPPRA500mg/5ml (100mg/ml) · Injectable | Levetiracetam | United States | Marketed | 2006 |
| KEPPRA100mg/ml · Solution | Levetiracetam | United States | Marketed | 2003 |
| KEPPRA1gm | 250mg | 500mg | 750mg · Tablet | Levetiracetam | United States | Marketed | 1999 |
| KEPPRA XR500mg | 750mg · Tablet, extended release | Levetiracetam | United States | Marketed | 2008 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 43 | 43 | 0 | CompaniesAll medicines |
The active substances in most of its medicines.
How the registers spell it, normalised: legal forms, accents and capitals removed.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.